Kyla N Price1, Jennifer L Hsiao2, Vivian Y Shi3. 1. University of Illinois College of Medicine, Chicago, Illinois, USA. 2. Division of Dermatology, Department of Medicine, University of California Los Angeles, Los Angeles, California, USA. 3. Division of Dermatology, Department of Medicine, University of Arizona, Tucson, Arizona, USA, vshi@email.arizona.edu.
Abstract
BACKGROUND: Hidradenitis suppurativa (HS) is an often-debilitating disease characterized by chronic and recurrent painful nodules, abscesses, and sinus tracts affecting the intertriginous areas. Despite evidence in the literature of varying prevalence of HS among different racial and ethnic groups, no studies have evaluated the overall generalizability of clinical trial results considering the increased prevalence of HS among African American populations. Additionally, there is a paucity of data exploring the distribution of race and ethnicity in randomized controlled trials (RCTs) for HS. The goal of this analysis is to explore the distribution of race and ethnicity in recent HS RCTs. SUMMARY: Using ClinicalTrials.gov and PubMed, race and ethnicity demographics were extracted from phase II and III trials published from 2000 to August 2019. Fifteen trials were included and among these trials 669 (68.0%) participants were Caucasian and 138 (14.0%) were of African descent. Asians, American Indian or Alaskan Natives, and Native Hawaiian or other Pacific Islanders comprised 29 (2.9%), 3 (0.3%), and 1 (0.1%) participant respectively. Only 15 participants were reported as Hispanic as only three trials reported ethnicity data. The remaining 144 (14.6%) participants were recorded as "other/unspecified" (36 self-identified, 108 lacked race reporting). None of the trials included sub-analysis of treatment efficacy based on race or ethnicity.
BACKGROUND:Hidradenitis suppurativa (HS) is an often-debilitating disease characterized by chronic and recurrent painful nodules, abscesses, and sinus tracts affecting the intertriginous areas. Despite evidence in the literature of varying prevalence of HS among different racial and ethnic groups, no studies have evaluated the overall generalizability of clinical trial results considering the increased prevalence of HS among African American populations. Additionally, there is a paucity of data exploring the distribution of race and ethnicity in randomized controlled trials (RCTs) for HS. The goal of this analysis is to explore the distribution of race and ethnicity in recent HS RCTs. SUMMARY: Using ClinicalTrials.gov and PubMed, race and ethnicity demographics were extracted from phase II and III trials published from 2000 to August 2019. Fifteen trials were included and among these trials 669 (68.0%) participants were Caucasian and 138 (14.0%) were of African descent. Asians, American Indian or Alaskan Natives, and Native Hawaiian or other Pacific Islanders comprised 29 (2.9%), 3 (0.3%), and 1 (0.1%) participant respectively. Only 15 participants were reported as Hispanic as only three trials reported ethnicity data. The remaining 144 (14.6%) participants were recorded as "other/unspecified" (36 self-identified, 108 lacked race reporting). None of the trials included sub-analysis of treatment efficacy based on race or ethnicity.
Authors: Moonyza A A Kamil; Nisha S Chandran; Sri Katon Sulistyaningrum; Murlidhar Rajagopalan; Sushil Tahiliani; Jennifer Hsiao; Haley Naik; Vivian Shi; John W Frew Journal: Int J Dermatol Date: 2020-05-20 Impact factor: 2.736
Authors: Terri Shih; Justine Seivright; Alyssa M Thompson; Swetha Atluri; Vivian Y Shi; Jennifer L Hsiao Journal: Int J Womens Dermatol Date: 2022-03-23
Authors: Devea R De; Alyssa M Thompson; Justine Seivright; Swetha Atluri; Amanda Ederle; Anna Swigert; Joanna Jaros; Jennifer L Hsiao; Vivian Y Shi Journal: Skin Appendage Disord Date: 2021-08-13
Authors: Dorra Bouazzi; Anette Bygum; Lone Skov; Mikkel Lindskov Sachs; Lars Iversen; Merete Hædersdal; Gregor B E Jemec; Simon F Thomsen Journal: Acta Derm Venereol Date: 2021-05-25 Impact factor: 3.875
Authors: Gautham Vellaichamy; Anya T Amin; Peter Dimitrion; Zaakir Hamzavi; Li Zhou; Indra Adrianto; Qing-Sheng Mi Journal: Front Genet Date: 2022-08-26 Impact factor: 4.772